Literature DB >> 11403335

Evidence that age-associated memory impairment is not a normal variant of aging.

W P Goldman1, J C Morris.   

Abstract

The concept of age-associated memory impairment (AAMI) suggests that clinically recognized memory dysfunction can be a feature of normal aging. To determine whether AAMI represents a variant of normal aging, we longitudinally studied individuals meeting AAMI criteria for development of dementia. Two hundred two community-living individuals (mean age, 77 years) with or without mild memory impairment were assessed annually for an average of 3 years at the Washington University Alzheimer's Disease Research Center. At baseline, no individual was unequivocally demented, as defined by a Clinical Dementia Rating (CDR) score of 1 or greater. Modified National Institute of Mental Health criteria were used to identify individuals with AAMI who otherwise met a criterion for cognitive normality. The Short Blessed Test (SBT) was used as a measure of general cognitive function; conservative (SBT = 5) and permissive (SBT = 10) cutoff scores were used as indicators of cognitive normality. With the more permissive measure of cognitive normality, 59 (29%) of the 202 individuals met AAMI criteria. Progression to dementia by 3 years occurred in 42% of AAMI individuals versus 16% of the individuals who did not meet AAMI criteria. With the more restrictive SBT cutoff of 5, 22% of individuals met AAMI criteria; progression to dementia occurred in 31% of these individuals versus 9% of the individuals without AAMI. Survival times to dementia differed significantly between AAMI and non-AAMI groups defined by either cutoff score. Our findings indicate that individuals with AAMI have a three-fold greater risk for development of dementia than individuals who do not meet AAMI criteria. Hence, AAMI may represent a dementia prodrome rather than a benign variant of aging.

Entities:  

Mesh:

Year:  2001        PMID: 11403335     DOI: 10.1097/00002093-200104000-00006

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  16 in total

1.  C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects.

Authors:  Jeremy M Silverman; Michal Schnaider Beeri; James Schmeidler; Clive Rosendorff; Gary Angelo; Rizalina S Mavris; Hillel T Grossman; Gregory A Elder; Jose Carrion-Baralt; Rebecca West
Journal:  Age Ageing       Date:  2009-01-15       Impact factor: 10.668

Review 2.  Brain aging, Alzheimer's disease, and mitochondria.

Authors:  Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-09-02

Review 3.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

4.  Homocysteine and cognitive function in very elderly nondemented subjects.

Authors:  Rebecca K West; Michal Schnaider Beeri; James Schmeidler; Dara B Mitchell; Katherine R Carlisle; Gary Angelo; Rizalina Mavris; Erik Langhoff; Clive Rosendorff; Jeremy M Silverman
Journal:  Am J Geriatr Psychiatry       Date:  2011-07       Impact factor: 4.105

5.  Alzheimer disease: are we intervening too late? Pro.

Authors:  Virginia Olga B Emery
Journal:  J Neural Transm (Vienna)       Date:  2011-06-07       Impact factor: 3.575

6.  Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.

Authors:  Susan M Resnick; Alvin M Matsumoto; Alisa J Stephens-Shields; Susan S Ellenberg; Thomas M Gill; Sally A Shumaker; Debbie D Pleasants; Elizabeth Barrett-Connor; Shalender Bhasin; Jane A Cauley; David Cella; Jill P Crandall; Glenn R Cunningham; Kristine E Ensrud; John T Farrar; Cora E Lewis; Mark E Molitch; Marco Pahor; Ronald S Swerdloff; Denise Cifelli; Stephen Anton; Shehzad Basaria; Susan J Diem; Christina Wang; Xiaoling Hou; Peter J Snyder
Journal:  JAMA       Date:  2017-02-21       Impact factor: 56.272

7.  Lessons From the Testosterone Trials.

Authors:  Peter J Snyder; Shalender Bhasin; Glenn R Cunningham; Alvin M Matsumoto; Alisa J Stephens-Shields; Jane A Cauley; Thomas M Gill; Elizabeth Barrett-Connor; Ronald S Swerdloff; Christina Wang; Kristine E Ensrud; Cora E Lewis; John T Farrar; David Cella; Raymond C Rosen; Marco Pahor; Jill P Crandall; Mark E Molitch; Susan M Resnick; Matthew Budoff; Emile R Mohler; Nanette K Wenger; Harvey Jay Cohen; Stanley Schrier; Tony M Keaveny; David Kopperdahl; David Lee; Denise Cifelli; Susan S Ellenberg
Journal:  Endocr Rev       Date:  2018-06-01       Impact factor: 19.871

8.  Heritability of cognitive functions in families of successful cognitive aging probands from the Central Valley of Costa Rica.

Authors:  Tiffany A Greenwood; Michal S Beeri; James Schmeidler; Daniel Valerio; Henriette Raventós; Lara Mora-Villalobos; Karla Camacho; José R Carrión-Baralt; Gary Angelo; Laura Almasy; Mary Sano; Jeremy M Silverman
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  Apolipoproteins E and C1 and brain morphology in memory impaired elders.

Authors:  J M Serra-Grabulosa; P Salgado-Pineda; C Junqué; C Solé-Padullés; P Moral; A López-Alomar; T López; A López-Guillén; N Bargalló; J M Mercader; I C Clemente; D Bartrés-Faz
Journal:  Neurogenetics       Date:  2002-12-21       Impact factor: 2.660

10.  ACE polymorphism and use of ACE inhibitors: effects on memory performance.

Authors:  Jaqueline B Schuch; Pamela C Constantin; Vanessa K da Silva; Camila Korb; Daiani P Bamberg; Tatiane J da Rocha; Marilu Fiegenbaum; Alcyr de Oliveira; Luciana A Tisser; Fabiana M de Andrade
Journal:  Age (Dordr)       Date:  2014-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.